DownloadHi-Res Photo

Zeynep Busra Zengin

Hospital Resident

Research & Publications
Biography

Coauthors

Selected Publications

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialEbrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin Z, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee P, Parks T, Takahashi M, Hayashi A, Kortylewski M, Caporaso J, Lee K, Tripathi A, Pal S. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2024, 1-10. PMID: 38942995, DOI: 10.1038/s41591-024-03086-4.
Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC).Barragán Carrillo R, Dizman N, Ebrahimi H, Meza L, Bergerot P, Dorff T, Hsu J, Zengin Z, Salgia N, Chehrazi-Raffle A, Tripathi A, Castro D, Mercier B, Caporaso G, Lee K, Pal S. Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC). Journal Of Clinical Oncology 2024, 42: 4521-4521. DOI: 10.1200/jco.2024.42.16_suppl.4521.
Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).Dizman N, Ebrahimi H, Barragán Carrillo R, Meza L, Bergerot P, Dorff T, Hsu J, Zengin Z, Castro D, Chehrazi-Raffle A, Tripathi A, Trent J, Takahashi M, Oka K, Higashi S, Caporaso G, Lee K, Pal S. Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: 4550-4550. DOI: 10.1200/jco.2024.42.16_suppl.4550.
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.Salgia N, Zengin Z, Pal S, Dizman N. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances. American Society Of Clinical Oncology Educational Book 2024, 44: e438642. PMID: 38776514, DOI: 10.1200/edbk_438642.
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic TherapyEbrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.
CRE24-052: Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic ChallengeLobo A, Zengin Z, Kenworthy C, Sharda A. CRE24-052: Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge. Journal Of The National Comprehensive Cancer Network 2024, 22 DOI: 10.6004/jnccn.2023.7326.
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialPal S, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama B, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin S, Loriot Y, Sridhar S, Sonpavde G, Fleming M, Lerner S, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. European Urology 2024 PMID: 38580518, DOI: 10.1016/j.eururo.2024.03.023.
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based CombinationsGebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus 2024 PMID: 38580524, DOI: 10.1016/j.euf.2024.03.006.
Barriers to Clinical Trial Implementation Among Community Care CentersEbrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia N, Zengin Z, Meza L, Chawla N, Castro D, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer R, Boehmer L, Pal S, Chehrazi-Raffle A. Barriers to Clinical Trial Implementation Among Community Care Centers. JAMA Network Open 2024, 7: e248739. PMID: 38683608, PMCID: PMC11059033, DOI: 10.1001/jamanetworkopen.2024.8739.
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZengin Z, Henderson N, Park J, Ali A, Nguyen C, Hwang C, Barata P, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer And Prostatic Diseases 2024, 1-7. PMID: 38383885, DOI: 10.1038/s41391-024-00805-3.
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).Barragan-Carrillo R, Chawla N, Salgia N, Meza L, Zengin Z, Li X, Dizman N, Ebrahimi H, Hsu J, Castro D, Mercier B, Dorff T, Tripathi A, Bergerot C, Bergerot P, Chehrazi-Raffle A, Pal S. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: tps491-tps491. DOI: 10.1200/jco.2024.42.4_suppl.tps491.
Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.Chawla N, Mercier B, Govindarajan A, Li X, Castro D, Ebrahimi H, Barragan-Carrillo R, Zang P, LeVee A, Dizman N, Hsu J, Meza L, Zengin Z, Salgia N, Chehrazi-Raffle A, Dorff T, Pal S, Tripathi A. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract. Journal Of Clinical Oncology 2024, 42: 682-682. DOI: 10.1200/jco.2024.42.4_suppl.682.
Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.
Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.Ebrahimi H, Meza L, Lee K, Malhotra J, Alcantara M, Zengin Z, Dizman N, Hsu J, Llamas-Quitiquit M, Castro D, Mercier B, Barragan-Carrillo R, Chawla N, Li X, Liu S, Chehrazi-Raffle A, Dorff T, Frankel P, Tripathi A, Pal S. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial. Journal Of Clinical Oncology 2024, 42: 460-460. DOI: 10.1200/jco.2024.42.4_suppl.460.
Association between thymectomy and incidence of renal cell carcinoma (RCC).Barragan-Carrillo R, Ebrahimi H, Chawla N, Salgia N, Castro D, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin Z, LeVee A, Tripathi A, Dorff T, Bergerot C, Bergerot P, Eilber K, Dallas K, Pal S. Association between thymectomy and incidence of renal cell carcinoma (RCC). Journal Of Clinical Oncology 2024, 42: 371-371. DOI: 10.1200/jco.2024.42.4_suppl.371.
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapyAlcantara M, Tang W, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal S, Kortylewski M. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. Frontiers In Immunology 2024, 14: 1274781. PMID: 38259453, PMCID: PMC10800835, DOI: 10.3389/fimmu.2023.1274781.
Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus NivolumabTripathi N, Meza L, Sayegh N, Govindarajan A, Byron S, Zhang J, Chigarira B, Jo Y, Zengin Z, Li H, Gebrael G, Desai A, Agarwal N, Swami U, Maughan B, Pal S. Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab. Kidney Cancer 2023, 7: 137-145. DOI: 10.3233/kca-230011.
Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers.Gebrael G, Zengin Z, Swami U. Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. JCO Precision Oncology 2023, 7: e2300397. PMID: 37972335, DOI: 10.1200/po.23.00397.
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell CarcinomaDizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal S. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 21: 530-536. PMID: 37495481, DOI: 10.1016/j.clgc.2023.06.004.
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.Ebrahimi H, Meza L, Lee K, Malhotra J, Alcantara M, Zengin Z, Dizman N, Govindarajan A, Hsu J, Llamas-Quitiquit M, Chawla N, Castro D, Mercier B, Liu S, Chehrazi-Raffle A, Dorff T, Frankel P, Li X, Pal S, Tripathi A. Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial. Journal Of Clinical Oncology 2023, 41: lba104-lba104. DOI: 10.1200/jco.2023.41.17_suppl.lba104.
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal StudyBergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).Meza L, Choi Y, Zhang J, Dizman N, Zengin Z, Ebrahimi H, Barragan-Carrillo R, Hsu J, Chawla N, Chehrazi-Raffle A, Tripathi A, Castro D, Mercier B, Govindarajan A, Chan A, Schork N, Byron S, Pal S. Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4561-4561. DOI: 10.1200/jco.2023.41.16_suppl.4561.
Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).Dizman N, Pathak K, Alcantara M, Meza L, Bergerot P, Willey M, Dorff T, Hsu J, Zengin Z, Castro D, Ebrahimi H, Chehrazi-Raffle A, Tripathi A, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Pirrotte P, Pal S. Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4556-4556. DOI: 10.1200/jco.2023.41.16_suppl.4556.
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchEbrahimi H, Castro D, Feng M, Prajapati S, Lee K, Chan E, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Meza L, Mercier B, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot C, Rock A, Liu S, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research. Clinical Genitourinary Cancer 2023, 21: e467-e473. PMID: 37301665, DOI: 10.1016/j.clgc.2023.05.013.
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell CarcinomaChehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, McDaniel T, Trent J, Baehner F, Murtaza M, Pal S. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200543. PMID: 37027813, PMCID: PMC10309555, DOI: 10.1200/po.22.00543.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort AnalysisMeza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal S. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist 2023, 28: e748-e755. PMID: 36971500, PMCID: PMC10485287, DOI: 10.1093/oncolo/oyad067.
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Li X, Agarwal N, Pal S. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 678-678. DOI: 10.1200/jco.2023.41.6_suppl.678.
Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).Ebrahimi H, Battle D, Zengin Z, Dizman N, Meza L, Castro D, Govindarajan A, Mercier B, Chawla N, Chehrazi-Raffle A, Tripathi A, Liu S, Vaishampayan U, Staehler M, Pal S. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 662-662. DOI: 10.1200/jco.2023.41.6_suppl.662.
Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).Barragan-Carrillo R, Dallas K, Tripathi A, Govindarajan A, Zengin Z, Meza L, Philip E, Castro D, Chehrazi-Raffle A, Chawla N, Hsu J, Dizman N, Eilber K, Bergerot C, Pal S. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC). Journal Of Clinical Oncology 2023, 41: 614-614. DOI: 10.1200/jco.2023.41.6_suppl.614.
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).Leong S, Ali S, Zengin Z, Meza L, Dizman N, Ebrahimi H, Govindarajan A, Castro D, Li X, Kim T, Melamed S, Onyshchenko M, Pal S, Chehrazi-Raffle A. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). Journal Of Clinical Oncology 2023, 41: 613-613. DOI: 10.1200/jco.2023.41.6_suppl.613.
Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.Prajapati S, Feng M, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 612-612. DOI: 10.1200/jco.2023.41.6_suppl.612.
Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy.Tripathi A, Barragan-Carrillo R, Philip E, Govindarajan A, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin Z, Bergerot C, Eilber K, Pal S, Dallas K. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy. Journal Of Clinical Oncology 2023, 41: 455-455. DOI: 10.1200/jco.2023.41.6_suppl.455.
Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.Castro D, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 453-453. DOI: 10.1200/jco.2023.41.6_suppl.453.
Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.Feng M, Prajapati S, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 34-34. DOI: 10.1200/jco.2023.41.6_suppl.34.
Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).Chehrazi-Raffle A, Tukachinsky H, Schrock A, Hwang J, Zengin Z, Meza L, Chawla N, Ebrahimi H, Govindarajan A, Castro D, Rock A, Tripathi A, Dorff T, Pal S, Oxnard G, Agarwal N, Antonarakis E. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). Journal Of Clinical Oncology 2023, 41: 220-220. DOI: 10.1200/jco.2023.41.6_suppl.220.
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell CarcinomaZengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey StudyCastro D, Zengin Z, Malhotra J, Bergerot C, Meza L, Dizman N, Govindarajan A, Hsu J, Chehrazi-Raffle A, Chawla N, Mercier B, Chen S, Feng M, Prajapati S, Lee K, Philip E, Dorff T, Lyou Y, Pal S. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study. Cancer Investigation 2023, 41: 70-76. PMID: 36239609, DOI: 10.1080/07357907.2022.2136683.
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint InhibitorsChawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.
880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC)Chehrazi-Raffle A, Alcantara M, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Castro D, Govindarajan A, Horsager A, Hsu J, Pal S, Kortylewski M. 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC). 2022, a917-a917. DOI: 10.1136/jitc-2022-sitc2022.0880.
810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockadeAlcantara M, Chehrazi-Raffle A, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Horsager A, Hsu J, Pal S, Kortylewski M. 810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockade. 2022, a846-a846. DOI: 10.1136/jitc-2022-sitc2022.0810.
1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Lyou Y, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, Trent J, Murtaza M, Pal S. 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC). Annals Of Oncology 2022, 33: s1223. DOI: 10.1016/j.annonc.2022.07.1582.
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZengin Z, Pal S, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Rini B. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer 2022, 20: 553-557. PMID: 36096984, DOI: 10.1016/j.clgc.2022.08.005.
Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinomaCastro D, Dizman N, Zengin Z, Malhotra J, Meza L, Muddasani R, Govindarajan A, Chawla N, Chehrazi-Raffle A, Hsu J, Bergerot P, Bergerot C, Dorff T, Lyou Y, Pal S. Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinoma. Cancer Research 2022, 82: 6293-6293. DOI: 10.1158/1538-7445.am2022-6293.
A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).Meza L, Malhotra J, Zengin Z, Dizman N, Hsu J, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Castro D, Dorff T, Lyou Y, Frankel P, Pal S. A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: tps4606-tps4606. DOI: 10.1200/jco.2022.40.16_suppl.tps4606.
Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.
Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).Ali S, Leong S, Meza L, Dizman N, Zengin Z, Kim T, Pak Y, Onyshchenko M, Pal S, Chehrazi-Raffle A. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo). Journal Of Clinical Oncology 2022, 40: 4554-4554. DOI: 10.1200/jco.2022.40.16_suppl.4554.
Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.Dizman N, Meza L, Bergerot P, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Malhotra J, Govindarajan A, Castro D, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity. Journal Of Clinical Oncology 2022, 40: 4510-4510. DOI: 10.1200/jco.2022.40.16_suppl.4510.
Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future DirectionsGovindarajan A, Castro D, Zengin Z, Salgia S, Patel J, Pal S. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers 2022, 14: 2049. PMID: 35565179, PMCID: PMC9106028, DOI: 10.3390/cancers14092049.
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialDizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2022, 28: 704-712. PMID: 35228755, PMCID: PMC9018425, DOI: 10.1038/s41591-022-01694-6.
Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.Chawla N, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Philip E, Bergerot C, Lyou Y, Swami U, Gupta S, Maughan B, Agarwal N, Pal S. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. Journal Of Clinical Oncology 2022, 40: 561-561. DOI: 10.1200/jco.2022.40.6_suppl.561.
Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC).Govindarajan A, Hegde A, Chawla N, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Castro D, Salgia S, Bergerot C, Tripathi N, Sayegh N, Philip E, Hsu J, Byron S, Pirrotte P, Pal S. Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2022, 40: 386-386. DOI: 10.1200/jco.2022.40.6_suppl.386.
Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.Meza L, Dizman N, Bergerot P, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Salgia N, Malhotra J, Chawla N, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study. Journal Of Clinical Oncology 2022, 40: 374-374. DOI: 10.1200/jco.2022.40.6_suppl.374.
Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).Meza L, Choi Y, Govindarajan A, Dizman N, Zengin Z, Hsu J, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Castro D, Chan A, Zhang G, Byron S, Highlander S, Schork N, Pal S. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 372-372. DOI: 10.1200/jco.2022.40.6_suppl.372.
Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Malhotra J, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment. Journal Of Clinical Oncology 2022, 40: 371-371. DOI: 10.1200/jco.2022.40.6_suppl.371.
Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.
Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.
Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.Malhotra J, Philip E, Govindarajan A, Salgia S, Meza L, Zengin Z, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 327-327. DOI: 10.1200/jco.2022.40.6_suppl.327.
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).Zengin Z, Henderson N, Park J, Ali A, Hwang C, Barata P, Bilen M, Graham L, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts). Journal Of Clinical Oncology 2022, 40: 138-138. DOI: 10.1200/jco.2022.40.6_suppl.138.
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinomaZengin Z, Chehrazi-Raffle A, Salgia N, Muddasani R, Ali S, Meza L, Pal S. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology Seminars And Original Investigations 2021, 40: 25-36. PMID: 34840077, DOI: 10.1016/j.urolonc.2021.10.003.
1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancersSalgia S, Malhotra J, Zengin Z, Meza L, Ely J, Hsu J, Kelley E, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Salgia N, Dizman N, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. 1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers. Annals Of Oncology 2021, 32: s1132. PMCID: PMC8454399, DOI: 10.1016/j.annonc.2021.08.1557.
1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)Zengin Z, Malhotra J, Salgia S, Dizman N, Yost S, Chawla N, Govindarajan A, Hsu J, Salgia N, Bergerot P, Meza L, Chehrazi-Raffle A, Muddasani R, Gillece J, Yuan Y, Highlander S, Pal S. 1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC). Annals Of Oncology 2021, 32: s1211. DOI: 10.1016/j.annonc.2021.08.1704.
Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern CaliforniaSalgia NJ, Chehrazi‐Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 2021, 10: 5671-5680. PMID: 34331372, PMCID: PMC8366095, DOI: 10.1002/cam4.4119.
Abstract LB196: Comparison of whole exome sequencing and targeted sequencing in patients with advanced bladder cancerChawla N, Zengin Z, Govindarajan A, Pal S. Abstract LB196: Comparison of whole exome sequencing and targeted sequencing in patients with advanced bladder cancer. Cancer Research 2021, 81: lb196-lb196. DOI: 10.1158/1538-7445.am2021-lb196.
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell CarcinomaZengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?Zengin Z, Meza L, Pal S, Grivas P. Chemoimmunotherapy in urothelial cancer: concurrent or sequential? The Lancet Oncology 2021, 22: 894-896. PMID: 34051179, DOI: 10.1016/s1470-2045(21)00284-9.
First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.Meza L, Dizman N, Bergerot P, Dorff T, Lyou Y, Frankel P, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Gillece J, Reining L, Trent J, Highlander S, Pal S. First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 4513-4513. DOI: 10.1200/jco.2021.39.15_suppl.4513.
Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.Chehrazi-Raffle A, Salgia N, Hsu J, Zengin Z, Salgia S, Chawla N, Malhotra J, Dizman N, Muddasani R, Meza L, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal S. Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis. Journal Of Clinical Oncology 2021, 39: 1538-1538. DOI: 10.1200/jco.2021.39.15_suppl.1538.
Editorial CommentZengin Z, Malhotra J, Pal S. Editorial Comment. Journal Of Urology 2021, 206: 251-251. PMID: 33940926, DOI: 10.1097/ju.0000000000001768.02.
Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.Zengin Z, Weipert C, Hsu J, Salgia N, Hensel C, Maughan B, Rathi N, Goel D, Agarwal N, Choueiri T, Pal S. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Journal Of Clinical Oncology 2021, 39: 347-347. DOI: 10.1200/jco.2021.39.6_suppl.347.
First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).Dizman N, Hsu J, Gillece J, Folkerts M, Reining L, Bergerot P, Meza L, Zengin Z, Muddasani R, Chawla N, Karimi M, Trent J, Highlander S, Pal S. First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO). Journal Of Clinical Oncology 2021, 39: 337-337. DOI: 10.1200/jco.2021.39.6_suppl.337.
645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitisDizman N, Greenberg M, Newman A, Skupsky J, Hsu J, Zengin Z, Salgia N, Meza L, Chawla N, Salgia S, Malhotra J, Pal S. 645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a682-a682. DOI: 10.1136/jitc-2020-sitc2020.0645.
Efficacy And Toxicity Of Radiotherapy For Oligoprogression Of Metastatic Renal Cell carcinoma (mRCC)Dandapani S, Salgia N, Dizman N, Zengin Z, Hsu J, Pal S. Efficacy And Toxicity Of Radiotherapy For Oligoprogression Of Metastatic Renal Cell carcinoma (mRCC). International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e879. DOI: 10.1016/j.ijrobp.2020.07.468.
Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testingZengin Z, Weipert C, Hsu J, Salgia N, Saam J, Choueiri T, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals Of Oncology 2020, 31: s553-s554. DOI: 10.1016/j.annonc.2020.08.773.
Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.Zengin Z, Salgia N, Chehrazi-Raffle A, Meza L, Malhotra J, Pal S. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. The Cancer Journal 2020, 26: 432-440. PMID: 32947311, DOI: 10.1097/ppo.0000000000000473.
Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).Zengin Z, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal S. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: e17100-e17100. DOI: 10.1200/jco.2020.38.15_suppl.e17100.
Tivozanib in renal cell carcinoma: a new approach to previously treated diseaseSalgia N, Zengin Z, Pal S. Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances In Medical Oncology 2020, 12: 1758835920923818. PMID: 32547647, PMCID: PMC7249546, DOI: 10.1177/1758835920923818.
Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?Şentürk Yikilmaz A, Akinci S, Bakanay Ş, Zengin Z, Dilek İ. Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic? Indian Journal Of Hematology And Blood Transfusion 2019, 36: 84-90. PMID: 32158089, PMCID: PMC7042443, DOI: 10.1007/s12288-019-01169-8.

Edit Profile

Zeynep Busra Zengin

Contact Information

Related Links

Research & Publications

Biography

Coauthors

Selected Publications